MAVENIR
8.9.2021 09:02:05 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced that Ontix, the UK based next-generation infrastructure-as-a-service provider, will be launching an Open RAN pilot for neutral host in-building connectivity in a central London office building, powered by Mavenir’s MAVair solution.
The Open RAN platform will be deployed at the Ontix Data Centre in London whilst the small cell units will be deployed at an Ontix’s customer building. The solution would enable Ontix to provide indoor mobile connectivity to typical areas like multi-tenanted offices, shopping malls, stadiums, hospitals, enterprise buildings and hot spots, delivering contiguous coverage and high-speed mobile connectivity to its enterprise customers and end consumers.
Delivering high-quality mobile connectivity indoors poses significant challenges to both operators and building owners, with a range of factors including the number of people in a building, construction materials and remote locations all impacting signal strength. It is imperative that any solution must provide service for all users, irrespective of the carrier they happen to be subscribed to, by using neutral host solutions.
Ontix and Mavenir will trial the delivery of a neutral host in-building, Open Virtualised Radio Access Network (Open vRAN) to provide enhanced connectivity. This includes the delivery and integration of Open RAN compatible, software upgradable small cells for enhanced in-building coverage and capacity.
“Open RAN is changing the dynamics of how cellular solutions are designed and delivered, and this deployment is at the cutting edge of the technology in the UK,” said Patrick Bradd, Chief Executive Officer at Ontix. “We are excited to be working on this ground-breaking Open RAN pilot to deploy a neutral host architecture to demonstrate its flexibility and how the use of commoditised hardware, can help to create the next generation of in-building networks.”
“Mavenir is delighted to partner with Ontix in addressing this demand from enterprises and consumers for mobile connectivity, especially in areas with poor indoor and in-building coverage. We are confident that using this innovative vRAN solution Ontix will be able to deliver a cost effective and a higher quality network to meet this growing demand,” said Stefano Cantarelli, Chief Marketing Officer at Mavenir.
The MAVair family includes Open vRAN designed with cloud-native virtualisation techniques, enabling the RAN to flex and adapt based on usage and coverage. Mavenir’s vRAN platform provides a fully scalable virtualised network architecture with open standard interfaces, providing neutral host solution providers the option of deploying radio units from different vendors. The vRAN platform uses software running on COTS (commercial off the shelf) hardware that provides cost effectiveness, more flexibility and agility to neutral host solution providers, whilst providing one architecture for many different user scenarios.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Ontix:
Ontix is a next-generation infrastructure-as-a-service provider, disrupting the business model for delivering lightning-fast connectivity wherever it is needed. Ontix makes it cheaper, easier and quicker for mobile operators and wireless network providers to add next-generation wireless networks through its turnkey solutions. Ontix is transforming the entire process for wireless network densification by investing in shared small cell infrastructure – including connectivity – and licensing this to operators.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005060/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 22:30:00 CEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
